Carregant...
Making the Right Choice: Optimizing rt-PA and eptifibatide lysis, an in vitro study
INTRODUCTION: Recombinant tissue plasminogen activator (rt-PA) is the only FDA approved lytic therapy for acute ischemic stroke. However, there can be complications such as intra-cerebral hemorrhage. This has led to interest in adjuncts such as GP IIb-IIIa inhibitors. However, there is little data o...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2946496/ https://ncbi.nlm.nih.gov/pubmed/20813398 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.thromres.2010.07.020 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|